A Pilot-Study With Low-dose hrIL-2 for the Treatment of Systemic Lupus Erythematosus
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02465580|
Recruitment Status : Unknown
Verified June 2015 by Zhanguo Li, Peking University People's Hospital.
Recruitment status was: Recruiting
First Posted : June 8, 2015
Last Update Posted : June 8, 2015
Peking University People's Hospital
Beijing ShuangLu Pharmaceutical Co., Ltd.
Information provided by (Responsible Party):
Zhanguo Li, Peking University People's Hospital
Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
|Recruitment Status :||Unknown|
|Estimated Primary Completion Date :||June 2017|
|Estimated Study Completion Date :||December 2017|
|Submission Cycle||Results Submitted to ClinicalTrials.gov||Results Returned after Quality Control Review|
February 18, 2018 |
(Canceled on September 21, 2018)
September 21, 2018
|February 12, 2019|
February 24, 2019 |
(Canceled on March 18, 2019)
March 18, 2019
|June 14, 2019|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
He J, Zhang R, Shao M, Zhao X, Miao M, Chen J, Liu J, Zhang X, Zhang X, Jin Y, Wang Y, Zhang S, Zhu L, Jacob A, Jia R, You X, Li X, Li C, Zhou Y, Yang Y, Ye H, Liu Y, Su Y, Shen N, Alexander J, Guo J, Ambrus J, Lin X, Yu D, Sun X, Li Z. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2020 Jan;79(1):141-149. doi: 10.1136/annrheumdis-2019-215396. Epub 2019 Sep 19.